Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more
Biotest Aktiengesellschaft - Asset Resilience Ratio
Biotest Aktiengesellschaft (BIESF) has an Asset Resilience Ratio of 1.27% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Biotest Aktiengesellschaft's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Biotest Aktiengesellschaft's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $18.00 Million | 1.27% |
| Total Liquid Assets | $18.00 Million | 1.27% |
Asset Resilience Insights
- Limited Liquidity: Biotest Aktiengesellschaft maintains only 1.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biotest Aktiengesellschaft Industry Peers by Asset Resilience Ratio
Compare Biotest Aktiengesellschaft's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Annual Asset Resilience Ratio for Biotest Aktiengesellschaft (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Biotest Aktiengesellschaft.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.82% | $11.70 Million | $1.43 Billion | +0.08pp |
| 2023-12-31 | 0.74% | $10.40 Million | $1.41 Billion | -0.93pp |
| 2022-12-31 | 1.66% | $20.00 Million | $1.20 Billion | +0.48pp |
| 2021-12-31 | 1.19% | $13.10 Million | $1.10 Billion | -0.40pp |
| 2020-12-31 | 1.58% | $17.90 Million | $1.13 Billion | -0.66pp |
| 2019-12-31 | 2.25% | $24.90 Million | $1.11 Billion | -1.99pp |
| 2018-12-31 | 4.24% | $44.20 Million | $1.04 Billion | +3.64pp |
| 2017-12-31 | 0.60% | $5.90 Million | $978.50 Million | -0.47pp |
| 2016-12-31 | 1.07% | $10.00 Million | $932.80 Million | -9.31pp |
| 2015-12-31 | 10.38% | $99.90 Million | $962.70 Million | +5.08pp |
| 2014-12-31 | 5.30% | $54.70 Million | $1.03 Billion | +5.31pp |
| 2012-12-31 | -0.01% | $-72.00K | $682.35 Million | +3.41pp |
| 2008-12-31 | -3.42% | $-20.22 Million | $592.04 Million | -- |